Thrombophilia and Hypercoagulability

Thrombophilia is a predisposition to thrombosis arising from a hypercoagulable state — a tilting of the hemostatic balance toward clot formation. It can be inherited, as with factor V Leiden or deficiencies of natural anticoagulants, or acquired, as with the antiphospholipid syndrome. Thrombophilia chiefly raises the risk of venous thromboembolism, and its effect is usually expressed only when combined with additional triggering factors.

Definition

Thrombophilia is an inherited or acquired tendency toward venous (and sometimes arterial) thrombosis, resulting from a hypercoagulable state in which procoagulant activity or loss of natural anticoagulant control shifts the hemostatic balance toward clot formation.

Scope

This entry covers the concept of the hypercoagulable state, the distinction between inherited and acquired thrombophilias, the major mechanisms involving loss of anticoagulant control, and the multifactorial nature of thrombosis risk. It treats thrombophilia as a reference topic and does not provide recommendations on testing, anticoagulation, or individual risk management.

Core questions

• What inherited and acquired defects produce a hypercoagulable state?
• Why is thrombosis usually multifactorial rather than caused by a single risk factor?
• How does loss of natural anticoagulant control, as in activated protein C resistance, promote thrombosis?

Key concepts

• Hypercoagulable state
• Inherited thrombophilia
• Acquired thrombophilia
• Factor V Leiden and activated protein C resistance
• Natural anticoagulant deficiencies (antithrombin, protein C, protein S)
• Antiphospholipid syndrome
• Multifactorial (multiple-hit) thrombosis risk

Mechanisms

Thrombosis develops when procoagulant forces outweigh the natural anticoagulant and fibrinolytic systems. Inherited thrombophilias commonly impair anticoagulant control: factor V Leiden renders activated factor V resistant to cleavage by activated protein C, and deficiencies of antithrombin, protein C, or protein S remove brakes on thrombin generation. The discovery of activated protein C resistance by Dahlbäck and its molecular basis in the factor V Leiden mutation by Bertina and colleagues (1994) established this paradigm. Acquired thrombophilias, such as the antiphospholipid syndrome, create a prothrombotic state through autoantibodies. In most people, an inherited or acquired predisposition causes thrombosis only when combined with additional provoking factors such as immobilization, surgery, pregnancy, or hormone use — the multifactorial model emphasized by Connors (2017).

Clinical relevance

Understanding thrombophilia explains why venous thromboembolism often follows a combination of a background predisposition and a transient trigger, and why the value of testing is debated given that results frequently do not change management. This entry describes the concept for reference and does not recommend whether or when to test for thrombophilia or how to anticoagulate.

Epidemiology

Inherited thrombophilias vary widely in frequency: factor V Leiden is relatively common in populations of European ancestry, while deficiencies of antithrombin, protein C, and protein S are rare but confer higher individual risk. Acquired thrombophilia, particularly antiphospholipid syndrome, contributes additionally to thrombosis burden. Most carriers of common inherited variants never experience thrombosis, underscoring the multifactorial nature of risk discussed by Connors (2017).

Evidence & guidelines

Reviews such as Connors (2017) summarize the evidence on which thrombophilias matter clinically and the limited situations in which testing may inform care. This entry references such sources for orientation and does not reproduce testing or treatment recommendations.

History

The modern understanding of inherited thrombosis advanced rapidly in the 1990s. Björn Dahlbäck described resistance to activated protein C as a common cause of familial thrombosis, and Bertina and colleagues (1994) identified the underlying factor V Leiden mutation, transforming a previously obscure area into a defined molecular field. These discoveries, building on earlier recognition of antithrombin, protein C, and protein S deficiencies, reframed thrombophilia as a study of failed anticoagulant control.

Debates

What is the clinical value of thrombophilia testing?

Testing for inherited and acquired thrombophilia is widely available, but its results often do not change management, and reviews caution against routine testing because it rarely alters decisions about the duration or intensity of anticoagulation.

Key figures

• Björn Dahlbäck
• Rogier Bertina
• Jean Connors

Seminal works

• bertina-1994
• dahlback-1995
• connors-2017

Frequently asked questions

What is the difference between inherited and acquired thrombophilia?

Inherited thrombophilia results from genetic variants such as factor V Leiden or deficiencies of natural anticoagulants, present from birth. Acquired thrombophilia develops later from conditions such as the antiphospholipid syndrome. Both increase the tendency to form clots.

If someone has a thrombophilia, will they definitely develop a clot?

No. Most people with a common inherited thrombophilia never develop thrombosis. Risk is multifactorial, and clots usually occur when a predisposition combines with additional triggers such as surgery, immobilization, pregnancy, or hormone use.